Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Trans-Resveratrol · JNS115

Small molecule · Activator of SIRT1 and NLRP3

Phase 2 Most advanced trial
1 Registered trials

What is Trans-Resveratrol?

Trans-resveratrol is a polyphenolic small molecule that activates SIRT1 to stimulate mitochondrial biogenesis and autophagy, while inhibiting NLRP3 inflammasome activation. It is studied in Parkinson's disease for its neuroprotective effects through enhanced mitochondrial dynamics and reduced neuroinflammation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
JNS115, JOTROLTM
Drug type
Small molecule
Targets
SIRT1, NLRP3
Mechanism
Activator of SIRT1 and NLRP3
Pathways
autophagy, mitophagy, mitochondrial biogenesis, inflammasome inhibition
Therapy area
Neurology
In trials of
JUNS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07592767 Phase 2 Parkinson's Disease Recruiting JUNS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Parkinson's Disease

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.